The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.
Abstract
The beta‐site amyloid precursor protein cleaving enzyme‐1 (BACE‐1) initiates the generation of amyloid‐β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti‐Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states. The BACE‐1 inhibitor CNP520 has a selectivity, pharmacodynamics, and distribution profile suitable for AD prevention studies. CNP520 reduced brain and cerebrospinal fluid (CSF) Aβ in rats and dogs, and Aβ plaque deposition in APP‐transgenic mice. Animal toxicology studies of CNP520 demonstrated sufficient safety margins, with no signs of hair depigmentation, retina degeneration, liver toxicity, or cardiovascular effects. In healthy adults ≥ 60 years old, treatment with CNP520 was safe and well tolerated and resulted in robust and dose‐dependent Aβ reduction in the cerebrospinal fluid. Thus, long‐term, pivotal studies with CNP520 have been initiated in the Generation Program. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition. Alzheimer's disease (AD) is a chronic neurodegenerative disorder with increasing incidence in the aging societies, but without any disease‐modifying treatment. Deposition of toxic forms of the protein Aβ in the brain is pathologic. Treatment with a BACE‐1 inhibitor may prevent Aβ deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides LY2886721, many other candidates have also reached late stages of clinical trials, including atabecestat (Phase 2/3),305 elenbecestat (Phase 3),306 lanabecestat (Phase 2/3)307,308 and umibecestat (Phase 2/3).309 However, all of them have failed to receive final approval to reach the market.”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [309]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Umibecestat (14, CNP520), a fourth-generation BACE1 inhibitor, initially showed good safety and tolerability in early clinical studies.444,445”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [445]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to other BACE-1 inhibitors, CNP520 (umibecestat (labeled as 11, Figure 5)) has been shown to reduce the burden of amyloid-beta plaques in preclinical animals; it is presently undergoing testing phases [157,166,167].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [167]
In the citing paper
“or because of a cognitive worsening in the patients, as in the case of Umibecestat (Neumann et al., 2018)”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as Neumann et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“…drugs that target Ab is therefore increasingly focused on treatment during the earlier stages of AD (the newly defined preclinical stage and during the stage of mild cognitive impairment) when the disease-modifying therapy targeting Ab presumably will be of greatest benefit (Selkoe & Hardy, 2016).”
BackgroundOn the size of the active site in proteases. I. Papain
Schechter, I., & Berger, A. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(67)80055-x · Cited by 5,204 · cited 1×
“BACE-1 shares high structural similarity with the catalytic and ligand binding sites of these enzymes; however, we increased selectivity for BACE-1 by exploiting the size differences of remote substrate binding pockets, in particular the extended S3 pocket (Schechter & Berger, 1967).”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“BACE-1 is a membrane-bound aspartyl protease required for the processing of the amyloid precursor protein (APP) to form the N-terminus of Ab peptides and the protein-soluble APPb (sAPPb) (Vassar et al, 1999).”
BackgroundScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“CNP520 robustly reduces human CSF Ab In humans, determination of the direct BACE-1 product sAPPb and of Ab peptides in CSF allows measurement of the effect of CNP520 on APP processing in the brain (Blennow et al, 2010).”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 2×
“Inhibition of BACE-1 is a promising disease-modifying strategy for AD, validated by human genetics (Jonsson et al, 2012).”
BackgroundPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610 · cited 1×
“…with a biomarker signature for ongoing Ab deposition both in the APOE4 non-carrier and in the carrier group, but the proportion was higher in the carrier group, in line with reports documenting an increased risk of early Ab deposition in APOE4 carriers (Jansen et al, 2015; Hollands et al, 2017).”
ResultHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“…enrolls people at risk of developing AD based on age and genotype (presence of the APOE4 gene), we investigated the ability of CNP520 to inhibit Ab40 generation preclinically in the APOE4-TR mouse model, in which the mouse Apoe gene is replaced by the human APOE4 gene (Castellano et al, 2011).”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e9316 | 2018 1 of 18 et al, 2018; Honig et al, 2018).”
MethodInfluential
Cited by
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“Besides LY2886721, many other candidates have also reached late stages of clinical trials, including atabecestat (Phase 2/3),(305) elenbecestat (Phase 3),(306) lanabecestat (Phase 2/ 3)(307,308) and umibecestat (Phase 2/3).(309) However, all of them have failed to receive final approval to reach the market.”
BackgroundJeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Al Balushi, K., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 247
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
“Various BACE1 inhibitors, such as verubecestat, umibecestat, and atabecestat have been developed, and their efficacy and pharmacodynamics have been investigated in animal models (Kennedy et al., 2016; Neumann et al., 2018; Koriyama et al., 2021).”
BackgroundA Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment
Das, B., & Yan, R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00613-7 · Cited by 201
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
“CNP520 has been reported to show an improved selectivity profile for BACE1 over BACE2 and other aspartic proteases, which it is hoped will reduce off-target side-effects observed in patients with earlier generation BACE inhibitors.(62) In healthy adults >60 years old, treatment with CNP520”
BackgroundPeng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S.-Y., Du, M.-Q., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 165
“The BACE-1 inhibitor, Umibecestat (CNP520), has high selectivity and brain penetration, and animal toxicology studies have shown that it has a sufficiently safe range without AEs such as hair loss, cardiovascular damage, or liver toxicity (Neumann et al., 2018).”
BackgroundTargeting Amyloidogenic Processing of APP in Alzheimer’s Disease
Zhao, J., Liu, X., Xia, W., Zhang, Y., & Wang, C. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00137 · Cited by 162
Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Pinheiro, L. M. V., & Faustino, C. M. C. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321163438 · Cited by 153
Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer’s disease
Thapa, P., Upadhyay, S. P., Suo, W. Z., Singh, V., Gurung, P., Lee, E. S., Sharma, R., & Sharma, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104681 · Cited by 166
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162
Drug development for alzheimer’s disease: Microglia induced neuroinflammation as a target
Dong, Y., Li, X., Cheng, J., & Hou, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030558 · Cited by 136
Canine Cognitive Dysfunction and Alzheimer’s Disease – Two Facets of the Same Disease?
Mihevc, S. P., & Majdič, G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00604 · Cited by 163
“A recent survey, using BACE1 inhibitor CNP520, demonstrated reduced brain and CSF Aβ in rats, dogs, and reduced CSF Aβ in humans and was assessed to be well tolerated in healthy adults and further clinical trials are ongoing (Neumann et al., 2018).”
Investigational BACE inhibitors for the treatment of Alzheimer’s disease
Imbimbo, B. P., & Watling, M. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1683160 · Cited by 132
Alić, I., Goh, P. A., Murray, A., Portelius, E., Gkanatsiou, E., Gough, G., Mok, K. Y., Koschut, D., Brunmeir, R., Yeap, Y. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0806-5 · Cited by 123
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
“In both animals and humans, umibecestat reduced Ab concentrations in CSF by up to 95% [38].”
BackgroundSelf-citationBACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?
Bazzari, F. H., & Bazzari, A. H. (2022) · Molecules · doi:10.3390/molecules27248823 · Cited by 132
“In a multi-center phase II (NCT02576639) dose-ranging safety and tolerability study in 2015 in subjects above 60 years old, CNP520 was found to be generally safe and well tolerated and resulted in a robust dose-dependent CSF Aβ reduction [107].”
BackgroundIraji, A., Khoshneviszadeh, M., Firuzi, O., Khoshneviszadeh, M., & Edraki, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103649 · Cited by 110
The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy
Ivanova, L. B., & Karelson, M. M. (2022) · Molecules · doi:10.3390/molecules27249041 · Cited by 132
“In this work, the X-ray structures of the recombinant human AChE (PDB ID: 4EY6) [36], human BACE1 (PDB ID: 6EQM) [39], human GSK3β (PDB ID: 1PYX) [41], ts3 human SERT (PDB IDs: 5I6X and 5I73) [43] and human TrkA (PDB ID: 4AOJ) [45] were downloaded from Protein Data Bank [64].”
González, J. F., Alcántara, A. R., Doadrio, A. L., & Sánchez-Montero, J. M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623201 · Cited by 98
“[53] resumes the state-of-the-art about BACE1 inhibitors reported in recent years but, currently, there are only two of them (shown in Figure 2) still at clinical stage: Elenbecestat [54] (E-2609, Eisai/Biogen), in Phase 3 (expected to finish by 2020) and CNP-520 [55] (Novartis/Amgen), in Phase 2/3 (finish not earlier…”
BackgroundBACE inhibitors in clinical development for the treatment of Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Sardone, R., Piccininni, C., Dibello, V., Stallone, R., Giannelli, G., Bellomo, A., Greco, A., et al. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1531706 · Cited by 92
Multipronged diagnostic and therapeutic strategies for Alzheimer's disease
Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 94
Wang, L., & Mao, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052360 · Cited by 97
“, verubescestat and CNP520), which decrease the rate of proteolytic cleavage of APP to Aβ, also showed promise in reducing Aβ load, but were unsuccessful in reducing cognitive decline or preventing future cognitive decline in cognitively normal older adults and AD patients [125,126,132].”
BackgroundThe emerging role of furin in neurodegenerative and neuropsychiatric diseases
Zhang, Y., Gao, X., Bai, X., Yao, S., Chang, Y., & Gao, G. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00313-1 · Cited by 85
Piccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 78
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 74
“CAD106 is a second-generation active A immunotherapy designed to induce antibody production against A 1–6 peptide fragments, avoiding the A -specific T-cell response [145]; whereas, CNP520 is an orally active -secretase (BACE-1) inhibitor that reduces A -peptide production [146].”
BackgroundSelective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
“Umibecestat (Novartis) ≥ 90% Aβ reduction in CSF at 85 mg Discontinued in 2019 (asymptomatic carriers of APOE-4) Worsens cognition, brain atrophy and weight loss (223) (187) www.”
BackgroundLimantoro, J., de Liyis, B. G., & Sutedja, J. C. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00751-2 · Cited by 243
“Moreover, umibecestat was reported to be safe and well tolerated in a multi-center phase II dose-ranging safety and tolerability trial in 2015 in participants over 60 years old, resulting in a substantial dose-dependent CSF Aβ decrease [133].”
BackgroundKoriyama, Y., Hori, A., Ito, H., Yonezawa, S., Baba, Y., Tánimoto, N., Ueno, T., Yamamoto, S., Yamamoto, T., Asada, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01917 · Cited by 62
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
“Similar to other BACE-1 inhibitors, CNP520 (umibeces-tat (labeled as 11 , Figure 5)) has been shown to reduce the burden of amyloid-beta plaques in preclinical animals; it is presently undergoing testing phases [157,166,167].”
BackgroundSmall-molecule drugs development for Alzheimer's disease
Yao, W., Yang, H., & Yang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1019412 · Cited by 57
“However, the clinical trials were discontinued lately in February 2018, as participants displayed worsened cognitive functions (Neumann et al., 2018).”
BackgroundFronza, M. G., Alves, D. A. C., Praticò, D., & Savegnago, L. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102033 · Cited by 49
Status and future directions of clinical trials in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 47
Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers
Kreiser, R. P., Wright, A. K., Block, N. R., Hollows, J. E., Nguyen, L. T., LeForte, K., Mannini, B., Vendruscolo, M., & Limbocker, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228651 · Cited by 51
“CNP520 (Umibecestat) Small molecule BACE1 inhibitor Reduces brain and CSF Aβ levels in rats, dogs, AD mice, and humans [219]; in a Phase 2/3 clinical trial”
BackgroundPeters, F., Salihoglu, H., Pratsch, K., Herzog, E., Pigoni, M., Sgobio, C., Lichtenthaler, S. F., Neumann, U., & Herms, J. (2019) · The EMBO Journal · doi:10.15252/embj.2019102345 · Cited by 44
“Thus, an adequate BACE inhibitor dosage that sufficiently suppresses A b production at plaques might already cause excessive inhibition of physiological BACE1 and BACE2 function elsewhere in the body.”
Self-citationFujimoto, K., Matsuoka, E., Asada, N., Tadano, G., Yamamoto, T., Nakahara, K., Fuchino, K., Ito, H., Kanegawa, N., Moechars, D., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00309 · Cited by 47
Gehlot, P., Kumar, S., Vyas, V. K., Choudhary, B. S., Sharma, M., & Malik, R. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117047 · Cited by 46
BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives
Coimbra, J. R. M., Resende, R., Custódio, J. B. A., Salvador, J. A. R., & Santos, A. E. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240146 · Cited by 51
Machauer, R., Lueoend, R., Hurth, K., Veenstra, S. J., Rueeger, H., Voegtle, M., Tintelnot-Blomley, M., Rondeau, J.-M., Jacobson, L. H., Laue, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01300 · Cited by 40
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 52
Pettus, L. H., Bourbeau, M. P., Bradley, J., Bartberger, M. D., Chen, K., Hickman, D., Johnson, M., Liu, Q., Manning, J. R., Nañez, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01034 · Cited by 37
Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer’s Disease
Wang, S., Kong, X., Chen, Z., Wang, G., Zhang, J., & Wang, J. (2022) · Molecules · doi:10.3390/molecules27134175 · Cited by 40
Kengkanna, A., & Ohue, M. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01155-w · Cited by 36
Tran, T., Tran, T., Tran, T., Mai, T.-T., Nguyen, N.-L., Thai, K., & Le, M.-T. (2020) · Molecules · doi:10.3390/molecules25184064 · Cited by 37
Baviskar, P. S., & Mahajan, H. S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102990 · Cited by 47
A new perspective on Alzheimer’s disease: m6A modification
Xia, L., Zhang, F., Li, Y., Mo, Y., Zhang, L., Li, Q., Luo, M., Hou, X., Du, Z., Deng, J., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1166831 · Cited by 34
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)
Rombouts, F. J. R., Kusakabe, K., Hsiao, C., & Gijsen, H. J. M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1832463 · Cited by 31
Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102595 · Cited by 38
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease
Zakaria, J. A. D., & Vassar, R. J. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809717 · Cited by 30
“Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 10: e9717 | 2018 1 of 3 Ab and Ab deposition in the brain, as measured through PET imaging, occur up to 25 and 15 years (respectively) prior to expected symptom onset.”
BackgroundMethodInfluentialPotential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer’s Disease
Tanaka, M., Saitô, S., Inoue, T., Satoh‐Asahara, N., & Ihara, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061992 · Cited by 32
Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Paniri, A., Hosseini, M. M., & Akhavan‐Niaki, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03626-y · Cited by 36
Advances in Drug Therapy for Alzheimer’s Disease
Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 38
Fujimoto, K., Yoshida, S., Tadano, G., Asada, N., Fuchino, K., Suzuki, S., Matsuoka, E., Yamamoto, T., Yamamoto, S., Ando, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01858 · Cited by 30
Treatment of Canine Cognitive Dysfunction With Novel Butyrylcholinesterase Inhibitor
Pipan, M. Z., Mihevc, S. P., Štrbenc, M., Košak, U., Ilić, I. G., Trontelj, J., Žakelj, S., Gobec, S., Pavlin, D., & Majdič, G. (2020) · Scientific Reports · doi:10.1038/s41598-021-97404-2 · Cited by 30
Elevation of plasma soluble amyloid precursor protein beta in Alzheimer’s disease
Yun, S., Cho, S.-J., Jo, C., Park, M. H., Han, C., & Koh, Y. H. (2019) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2019.103995 · Cited by 29
Is It the Twilight of BACE1 Inhibitors?
Hrabinova, M., Pejchal, J., Kucera, T., Jun, D., Schmidt, M., & Soukup, O. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200503023323 · Cited by 28
“, umibecestat is ~3-‐, ~20,000-‐ and ~6,000-‐fold more selective for BACE1 than for BACE2, CatD, and CatE, respectively [169].”
BackgroundBridging the Gap between Alzheimer’s Disease and Alzheimer’s-like Diseases in Animals
Gołaszewska, A., Bik, W., Motyl, T., & Orzechowski, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071664 · Cited by 34
“Such therapies in AD could be purportedly secretase inhibitor + immunotherapy; aggregation inhibitor + secretase inhibitor, and others [117].”
BackgroundQiu, R., Ahn, J. E., Alexander, R., Brodney, M. A., He, P., Leurent, C., Mancuso, J., Margolin, R. A., Tankisheva, E., & Chen, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190228 · Cited by 27
“724 As BACE1 inhibition typically requires a basic 725 amine for interaction with the catalytic aspartic acids 726 at the active site of the BACE1 enzyme [40], BACE 727 inhibitors in general are potential hERG ligands [36].”
BackgroundInfluentialAnti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
Ivanova, L. B., Karelson, M. M., & Dobchev, D. A. (2020) · Molecules · doi:10.3390/molecules25081846 · Cited by 23
BACE2: A Promising Neuroprotective Candidate for Alzheimer’s Disease
Yeap, Y. J., Kandiah, N., Nižetić, D., & Lim, K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220867 · Cited by 27
“and BACE2 [13, 91, 92], which might in part explain”
BackgroundMumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 24
Ugbaja, S. C., Sanusi, Z. K., Appiah‐Kubi, P., Lawal, M. M., & Kumalo, H. M. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106536 · Cited by 24
Ueno, T., Matsuoka, E., Asada, N., Yamamoto, S., Kanegawa, N., Ito, M., Ito, H., Moechars, D., Rombouts, F. J. R., Gijsen, H. J. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00359 · Cited by 22
Early Aβ reduction prevents progression of cerebral amyloid angiopathy
Schelle, J., Wegenast‐Braun, B. M., Fritschi, S. K., Kaeser, S. A., Jährling, N., Eicke, D., Skodras, A., Beschörner, N., Obermueller, U., Häsler, L. M., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25562 · Cited by 23
“NB-360 has not been tested in humans; however, exposures to NB-360 are very comparable to the BACE inhibitor CNP520.(36,37) CNP520 treatment of humans (90mg/day, repeated dosing) resulted in ~1μM blood levels, a blood concentration that is close to the concentration of NB-360 in mice with the current dosing FIGURE 5:…”
ResultSelf-citationTariot, P. N., Riviere, M., Salloway, S., Burns, J. M., Snædal, J., Borowsky, B., Lopez, C. L., Liu, F., Rouzade‐Dominguez, M., Cazorla, P., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14237 · Cited by 22
Self-citationArmbrust, F., Bickenbach, K., Marengo, L., Pietrzik, C. U., & Becker‐Pauly, C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2021.119164 · Cited by 22
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics
Arar, S. H., Haque, M. A., & Kayed, R. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26561 · Cited by 23
“241,242”
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Iram, F., Shahid, M., Ansari, J., Ashraf, G. M., Hassan, M. I., & Islam, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102342 · Cited by 22
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
Ulku, I., Leung, R., Herre, F., Walther, L., Shobo, A., Säftig, P., Hancock, M. A., Liebsch, F., & Multhaup, G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107510 · Cited by 22
Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360
Rueeger, H., Lueoend, R. M., Machauer, R., Veenstra, S. J., Holzer, P., Hurth, K., Voegtle, M., Frederiksen, M. U., Rondeau, J., Tintelnot‐Blomley, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02143 · Cited by 18
Self-citationTsai, Y., Kao, S.-T., & Cheng, C.-Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911311 · Cited by 22
Pterostilbene: A natural neuroprotective stilbene with anti-Alzheimer's disease properties
Gao, S., Zhang, H., Li, N., Zhang, L., Zhu, Z., & Xu, C. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101043 · Cited by 21
The Alzheimer’s disease–linked protease BACE2 cleaves VEGFR3 and modulates its signaling
Schmidt, A., Hrupka, B. J., van Bebber, F., Kumar, S. S., Feng, X., Tschirner, S. K., Aßfalg, M., Müller, S. A., Hilger, L. S., Hofmann, L. I., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170550 · Cited by 18
“A β 40 was quantified using a Human β Amyloid (aa 1–40) ELISA Kit (Wako) and A β 42 was quantified using a Human β Amyloid (aa 1–42) ELISA High Sensitive Kit (WAKO) according to the manufacturer’s protocols.”
Resende, R., Ferreira‐Marques, M., Moreira, P., Coimbra, J. R. M., Baptista, S. J., Isidoro, C., Salvador, J. A. R., Dinis, T. C. P., Pereira, C., & Santos, A. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200381 · Cited by 17
The Development of Pharmacological Therapies for Alzheimer’s Disease
Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 17
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 17
“Umibecestat (CNP520) β-secretase Phase 2/3 (NCT03131453; NCT02565511) Cognitive function decreased slightly, brain atrophy increased, weight loss Discontinued [63,64]”
BackgroundBACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer’s disease
Arya, R., Jain, S., Paliwal, S., Madan, K., Sharma, S. K., Mishra, A., Tiwari, P. K., & Kadiri, S. K. (2024) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/apjtb.apjtb_192_24 · Cited by 20
Amyloid-beta Targeted Therapeutic Approaches for Alzheimer’s Disease: Long Road Ahead
Dai, Y., Lei, C., Zhang, Z., Qi, Y., Lao, K., & Gou, X. (2022) · Current Drug Targets · doi:10.2174/1389450123666220421124030 · Cited by 16
Gupta, S. P., & Patil, V. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200416091623 · Cited by 17
The searching for agents for Alzheimer’s disease treatment via the system of self-consistent models
Toropov, A. A., Toropova, A. P., Achary, P. G. R., Rašková, M., & Raška, I. (2022) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2022.2053918 · Cited by 14
Elisée, E., Gapsys, V., Mele, N., Chaput, L., Selwa, E., de Groot, B. L., & Iorga, B. I. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00232-w · Cited by 13
“Analysis of Protein Data Bank [18] revealed 341 available crystal structures of human BACE but only 337 of them, including four synthetic structures (1M4H [19], 4TRW [20], 4TRY [20], 4TRZ [20]), were considered in this work since two structures were not released when the panel of proteins has been built (6EQM [21] and…”
BackgroundZBTB20-AS1 promoted Alzheimer's disease progression through ZBTB20/GSK-3β/Tau pathway
Wang, Y., Cai, M., Lou, Y., Zhang, S., & Liu, X. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.107 · Cited by 14
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Emerging paradigms in Alzheimer's therapy
Agnes Preethy, H., Rajendran, K., Sukumar, A. J., & Krishnan, U. M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176872 · Cited by 18
Stem cell therapy in Alzheimer’s disease: current status and perspectives
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440334 · Cited by 19
Klonarakis, M., Vos, M. D., Woo, E. K., Ralph, L. T., Thacker, J. S., & Gil‐Mohapel, J. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104541 · Cited by 15
Insights for Alzheimer's disease pharmacotherapy and current clinical trials
do Nascimento, A. L. C. S., Fernandes, R. P., Carvalho, A. C. S., Frigieri, I., Alves, R. C., & Chorilli, M. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105401 · Cited by 14
Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimer’s: A Review
Mehendale-Munj, S., & Patil, P. B. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666221228140450 · Cited by 13
Riluzole and Its Prodrugs for the Treatment of Alzheimer’s Disease
Al‐Horani, R. A. (2023) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2023-0001 · Cited by 13
Zamanian, M. Y., Khachatryan, L., Heidari, M., Darabi, R., Golmohammadi, M., Al-Aouadi, R. F. A., & Akkol, E. K. (2025) · BioFactors · doi:10.1002/biof.70047 · Cited by 15
Metadata
- Authors
- Neumann, U., Ufer, M., Jacobson, L. H., Rouzade‐Dominguez, M., Huledal, G., Kolly, C., Lüönd, R. M., Machauer, R., Veenstra, S. J., Hurth, K., Rueeger, H., Tintelnot‐Blomley, M., Staufenbiel, M., Shimshek, D. R., Perrot, L., Frieauff, W., Dubost, V., Schiller, H., Vogg, B., Beltz, K., Avrameas, A., Kretz, S., Pezous, N., Rondeau, J., Beckmann, N., Hartmann, A., Vormfelde, S., David, O. J., Galli, B., Ramos, R., Graf, A., & Lopez Lopez, C.
- Affiliations
- Novartis (Switzerland) (CH)
- Corresponding author
- Neumann, Ulf
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2018-09-17
- Volume
- 10
- Issue
- 11
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC6220303
- OpenAlex
- W2890206141
- Cited by
- 177
- References
- 65
- Citations by year
- 2026: 7 · 2025: 23 · 2024: 34 · 2023: 20 · 2022: 24 · 2021: 23 · 2020: 23 · 2019: 19 · 2018: 3
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Novartis Pharma AG, Basel, Switzerland
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- BACE1 inhibitors, Alzheimer's disease, amyloid-beta, amyloid hypothesis, disease prevention, early Alzheimer's disease, cerebrospinal fluid amyloid-beta, APP transgenic mice, veterinary toxicology, drug safety, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Astrocytes, Brain, Cathepsin D, Cerebral Hemorrhage, Female, Humans, Inflammation, Male, Mice, Inbred C57BL, Mice, Transgenic, Oxazines, Hominidae, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Microglia, Amyloid Precursor Protein Secretases, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.